Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00324155
Status:
COMPLETED
Last Update Posted:
2014-11-02
First Post:
2006-05-08
Brief Title:
Dacarbazine and Ipilimumab vs Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb